UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-27945

DOUGHERTY’S PHARMACY, INC.

(Exact name of registrant as specified in its charter)

Delaware		75-2900905
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

5924 ROYAL LANE SUITE 250

DALLAS, TEXAS 75230

(Address of principal executive offices) (Zip code)

972-250-0945

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company x
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Number of shares of common stock, $0.0001 par value, of registrant outstanding at August 1, 2018: 23,097,914

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	FINANCIAL STATEMENTS	3

	Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017	3

	Consolidated Statements of Operations for the Three and Six Months ended June 30, 2018 and 2017	4

	Consolidated Statements of Cash Flows for the Six Months ended June 30, 2018 and 2017	5

	Notes to Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 4.	Controls and Procedures	19

PART II. OTHER INFORMATION		20

Item 1.	Legal Proceedings	20

Item 6.	Exhibits	20

SIGNATURES		21

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Balance Sheets

(000’s omitted, except par value and share amounts)

	June 30,			December 31,
	2018			2017
	(Unaudited)			(Audited)
ASSETS

Current Assets
Cash	$	54		$	86
Restricted cash		–			303
Trade accounts receivable, net		1,549			1,673
Other receivables		374			345
Receivable from affiliates		4			6
Inventories, net		3,174			3,562
Prepaid expenses		151			267
Total current assets		5,306			6,242
Long term receivable		448			448
Property and equipment, net		1,022			1,045
Intangible assets, net		2,557			2,892
Deferred tax asset		2,000			2,000
Total assets	$	11,333		$	12,627

LIABILITIES

Current Liabilities
Accounts payable	$	2,988		$	3,123
Accrued liabilities		429			429
Notes payable, current portion		609			813
Revolving credit facility		3,861			3,831
Total current liabilities		7,887			8,196
Notes payable, long-term portion		2,520			2,801
Total liabilities		10,407			10,997

STOCKHOLDERS' EQUITY

Stockholders' equity:
Preferred stock, $0.0001 par value; 7,500,000 shares authorized: none issued and outstanding
Common stock, $0.0001 par value; 50,000,000 shares authorized; 24,112,164 shares issued and 23,082,164 shares outstanding at June 30, 2018; 24,003,310 shares issued and 22,973,310 shares outstanding at December 31, 2017		2			2
Additional paid-in capital		60,214			60,221
Accumulated deficit		(58,893	)		(58,196	)
Treasury stock, at cost, 1,030,000 shares		(397	)		(397	)
Total stockholders' equity		926			1,630
Total liabilities and stockholders' equity	$	11,333		$	12,627

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Statements of Operations

(000’s omitted, except share and per share amounts)

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017

Revenue	$	9,168		$	10,211		$	18,623		$	20,266
Cost of sales (exclusive of depreciation and amortization shown separately down below)		6,894			7,448			13,781			14,716
Gross profit		2,274			2,763			4,842			5,550

Operating expenses
Selling, general and administrative expenses		2,430			2,616			4,948			5,188
Non-cash stock compensation		2			11			(7	)		15
Depreciation and amortization		240			254			482			520
Total operating expenses		2,672			2,881			5,423			5,723
Operating loss		(398	)		(118	)		(581	)		(173	)

Other income		51			–			88			–
Interest income		33			12			33			12
Interest expense		(111	)		(112	)		(221	)		(214	)
Loss on disposal of assets and investment impairment		–			(75	)		–			(75	)
Loss before provision for income tax		(425	)		(293	)		(681	)		(450	)
Income tax provision		(6	)		(12	)		(16	)		(23	)
Net loss	$	(431	)	$	(305	)	$	(697	)	$	(473	)


Basic and diluted net loss per share attributable to common stockholders	$	(0.02	)	$	(0.01	)	$	(0.03	)	$	(0.02	)
Weighted-average number of shares-basic and diluted		23,076,964			22,455,471			23,082,064			22,436,615

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Statements of Cash Flows

(000’s omitted)

(Unaudited)

	Six Months Ended June 30,
	2018			2017
Operating Activities
Net loss	$	(697	)	$	(473	)
Items not requiring (providing) cash
Loss from disposal of assets		–			75
Depreciation and amortization		482			520
Stock-based compensation		(7	)		15
Changes in operating assets and liabilities:
Accounts receivable		126			87
Inventories		388			(140	)
Prepaid expenses and other assets		87			(56	)
Accounts payable		(135	)		367
Accrued liabilities		–			77

Net cash provided by operating activities		244			472

Investing Activities
Purchases of property and equipment		(124	)		(73	)
Cash received upon disposition of pharmacy		–			274
Cash received upon disposition of CPOC		–			617

Net Cash (used in) provided by investing activities		(124	)		818

Financing Activities
Payments on notes payable		(8,411	)		(10,326	)
Proceeds from notes payable		7,956			9,426

Net cash used in financing activities		(455	)		(900	)

Net (decrease) increase in cash		(335	)		390

Cash, beginning of period		389			361
Cash, end of period	$	54		$	751

Supplemental Cash Flow Information
Cash paid for income taxes	$	24		$	40
Cash paid for interest	$	220		$	204

Reconciliation of Cash to the Consolidated Balance Sheets
Cash	$	54		$	523
Restricted cash		–			303
Total cash	$	54		$	826

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Notes to Consolidated Financial Statements

1. Organization and Significant Accounting Policies

Description of Business

Dougherty’s Pharmacy, Inc. (“Dougherty’s” or the “Company”) is a value oriented company focused on successfully acquiring, managing and growing community based pharmacies in the Southwest Region. Dougherty’s was incorporated in Delaware on August 8, 2000.

A summary of the Company’s investments at Dougherty’s, is shown in the table below:

Date	Entity	Transaction Description	% Ownership

March 2004	Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)	Acquisition of retail pharmacy	100%

September 2010	ASDS of Orange County, Inc. (“ASDS”),	Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)	100%

On February 7, 2017, CRESA Partners of Orange County, L.P., an affiliate of Cresa Partners-West, Inc. was acquired by Savills Studley, Inc. liquidating the partnership interest in its entirety held by ASDS. ASDS remains active as a holding company for the remaining payouts.

On May 6, 2017, the Company sold its pharmacy in Humble, Texas, acquired in September 2014, and received total cash proceeds of $274,000 related to this transaction. The revenues and earnings of the pharmacy are not significant to the consolidated financial statements taken as a whole.

On February 6, 2018, the Company opened a new retail pharmacy location at The Campus at Legacy West in Plano, Texas (“Legacy”). This new location will offer pharmacy services and retail products to approximately 3,000 JCPenney Home Office employees and will be open to all other future tenants and visitors of The Campus at Legacy West. Dougherty’s is initially filling prescriptions via concierge service from its pharmacy on Campbell Road until Legacy completes its third party contract enrollment process. Dougherty’s anticipates first year revenues from the new location of less than $1.0 million as the pharmacy establishes itself at the new location.

Our business has historically required us to rely on cash flow from operations and upon borrowing under a $4,000,00 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (“the Lender”) as our primary sources of funding to operate and meet our financial obligations. Historically, much of our debt, including the Revolver, has been renewed or refinanced in the ordinary course of business. However, on August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,193 plus $18,252 in accrued and unpaid interest under the Revolver. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,251.80 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver. On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, entering into a settlement or workout arrangement with the Current Lender, or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company.

We have historically maintained a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we have managed our cash and capital structure to maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, and future investments or acquisitions. As of June 30, 2018 we had cash of approximately $54,000, working capital of approximately negative $2.6 million and total outstanding debt of $7.0 million, including $3.9 million for the revolving credit facility. Negative working capital is due to the reclassification of the revolving credit facility to current liabilities to present the consolidated financial statements in conformity with GAAP. The reclassification does not affect the representation of the Company’s overall performance. Cash provided from operating activities for the six months ended June 30, 2018 was $244,000. However, the Company’s default under the Revolver will have a material adverse effect on the Company’s liquidity and capital resources. Please See Note 6.

Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of Dougherty’s and all subsidiaries for which the Company has a controlling financial interest. Dougherty’s uses the cost method of accounting to recognize investments in and income from entities where Dougherty’s does not have a significant influence. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared by the Company, in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X, and have not been audited. Accordingly, these unaudited consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Registration Statement on Form 10. In the opinion of management, the interim unaudited consolidated financial statements included herein contain all adjustments, including normal recurring adjustments, considered necessary to present fairly the Company’s financial position, the results of operations and cash flows for the periods presented. Due to seasonality, the results of operations for the three months ended June 30, 2018, are not necessarily indicative of the results to be expected for any future interim period for the year ending December 31, 2018.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk

The Company’s credit risk relates primarily to its trade accounts receivables and its receivables from affiliates, along with cash deposits maintained at financial institutions in excess of federally insured limits on interest bearing accounts. Management performs continuing evaluations of debtors’ financial condition and maintains an allowance for uncollectible accounts as determined necessary.

Accounts Receivable

Receivables recorded in the financial statements represent valid claims against debtors for services rendered or other charges arising on or before the balance sheet date. Management makes estimates of the collectibility of accounts receivable. Specifically, management analyzes accounts receivable and historical bad debts, customer credit-worthiness, current economic trends, and changes in customer payment terms and collections trends when evaluating the adequacy of the allowance for doubtful accounts. Any change in the assumptions used in analyzing accounts receivable may result in additional allowances for doubtful accounts being recognized in the periods in which the change in assumptions occurs.

At June 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.

Inventories

Inventories consist of health care product finished goods held for resale, valued at the lower of cost using the first-in, first-out method or net realizable value. The Company maintains an estimated reserve against inventory for excess, slow-moving, and obsolete inventory as well as inventory for which carrying value is in excess of its net realizable value.

Long-Lived Assets

The Company evaluates the recoverability of the carrying value of its long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value.

Revenue Recognition

Revenues generated by the retail pharmacy operations are reported at the estimated net realizable amounts expected to be received from individuals, third-party payors, institutional health care providers and others. The Company recognizes revenue from the sale of pharmaceutical products and retail merchandise as transactions occur and product is delivered to the customer. Revenue from product sales is recognized at the point of sale and service revenue is recognized at the time services are provided.

Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.

Substantially all revenues earned during the six months ended June 30, 2018 and 2017, were earned from the retail pharmacy operations.

Cost of Sales

Cost of sales includes the purchase price of goods sold, prescription packaging, compounded prescription direct labor, inventory obsolescence, freight costs, cash discounts and vendor rebates. Rebates or refunds received by the Company from its suppliers are considered as an adjustment of the prices of the supplier’s products purchased by the Company.

Income Taxes

The Company accounts for income taxes in accordance with income tax accounting guidance (ASC 740, Income Taxes). The income tax accounting guidance results in two components of income tax expense: current and deferred. Current income tax expense reflects taxes to be paid or refunded for the current period by applying the provisions of the enacted tax law to the taxable income or excess of deductions over revenues. The Company determines deferred income taxes using the liability (or balance sheet) method. Under this method, the net deferred tax asset or liability is based on the tax effects of the differences between the book and tax bases of assets and liabilities, and enacted changes in tax rates and laws are recognized in the period in which they occur. Deferred income tax expense results from changes in deferred tax assets and liabilities between periods. Deferred tax assets are reduced by a valuation allowance if, based on the weight of evidence available, it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.

Tax positions are recognized if it is more-likely-than-not, based on the technical merits, that the tax position will be realized or sustained upon examination. The term more-likely-than-not means a likelihood of more than 50%; the terms examined and upon examination also include resolution of the related appeals or litigation processes, if any. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management’s judgment.

On December 22, 2017, the President signed into law the “Tax Cuts and Jobs Act” (the “TCJA”). Among numerous changes to existing tax laws, the TCJA permanently reduces the federal corporate income tax rate from 35% to 21% effective January 1, 2018. The effects on deferred tax balances of changes in tax rates are required to be taken into consideration in the period in which the changes are enacted, regardless of when they are effective. As the result of the reduction of the corporate income tax rate under the TCJA, the Company estimated the revaluation of its net deferred tax assets and recorded a provisional noncash income tax loss of approximately $1.0 million for year ended December 31, 2017. The Company has not completed all of its processes to determine the TCJA’s final impact. The final impact may differ from this provisional amount due to, among other things, changes in interpretations and assumptions the Company has made thus far and the issuance of additional regulatory or other guidance. The accounting is expected to be completed by the time the 2017 federal income tax return is filed in 2018.

Earnings per Share

Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss and unrecognized stock based compensation by the weighted-average number of common shares outstanding during the period and the unvested restricted stock units. The unrecognized stock based compensation as of June 30, 2018 and 2017 is $19,000 and $127,000, respectively; the unvested restricted stock units is 140,150 and 658,500, respectively. Due to the net losses for both years, restricted stock units for 2018 and 2017 were anti-dilutive.

New Accounting Pronouncements

ASU No. 2016-02, Leases (Topic 842)

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 requires the lessee to recognize assets and liabilities for leases with lease terms of more than twelve months. For leases with a term of twelve months or less, the Company is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Further, the lease requires a finance lease to recognize both an interest expense and an amortization of the associated expense. Operating leases generally recognize the associated expense on a straight line basis. ASU 2016-02 requires the Company to adopt the standard using a modified retrospective approach and becomes effective on January 1, 2019. The Company is currently evaluating the impact that ASU 2016-02 will have on its financial position, results of operations and cash flows. Our current minimum lease commitments are disclosed in Note 4.

2. Notes Payable

Notes payable consist of the following:

	June 30, 2018			December 31, 2017
		(Unaudited)			(Audited)

First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets
Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at June 30, 2018)	$	3,861,000		$	3,831,000
Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.		266,000			335,000
Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.6% (7.6% at June 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.		1,280,000			1,371,000
Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.6% (7.6% at June 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.		807,000			869,000
Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.38% at June 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.		533,000			570,000
Term note in the principal amount of $305,350 with interest payable at prime plus 2.4% (7.4% at June 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.		186,000			202,000
Acquisition Notes Payable, unsecured
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.		12,000			97,000
Insurance notes payable, secured by the respective insurance policies
Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%		45,000			170,000
		6,990,000			7,445,000
Less current portion		(4,470,000	)		(4,644,000	)
	$	2,520,000		$	2,801,000

Future maturities of notes payable at June 30, 2018, are as follows:

2018	$	4,470,000
2019		1,222,000
2020		1,298,000
	$	6,990,000

The revolving credit facility (“the Revolver”) with the First National Bank of Omaha (“the Lender”) is secured by, but not limited to, the accounts receivable, inventory, and the fixed assets of the Borrowers. On July 1, 2017, the Company obtained an extension of the Revolver, through September 1, 2017. On August 9, 2017, the Company obtained an additional term for the Revolver in the amount of $4,450,000 effective September 1, 2017, and then effective February 1, 2018, in the amount of $4,000,000. Outstanding advances under the Revolver bore interest at LIBOR plus 3.25% (5.24% at June 30, 2018); accrued and unpaid interest on the Revolver was due monthly. All outstanding principal under the Revolver plus all accrued and unpaid interest thereon was due and payable in full on August 1, 2018 (See Note 6). On August 10, 2018, the Lender notified the Company that the Revolver had been sold to the Current Lender effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Revolver is secured by certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company. The Revolver is subject to certain financial restrictions, now subject to the Current Lender’s prior written approval, including, but not limited to, capital expenditures not to exceed $200,000, additional indebtedness, acquisitions of entities and payment of dividends and distributions. Effective December 31, 2017, the Borrowers agreed to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined. As of June 30, 2018 the Borrowers were not in compliance with this financial covenant.

3. Stock and Share-Based Compensation

Restricted Share Unit Incentive Plan

On November 13, 2013, the Board of Directors approved and adopted the Restricted Share Unit (“RSU”) Incentive Plan. Under the plan the Company can award RSUs to employees and non-employee directors and consultants pursuant to restricted stock agreements contingent upon continuous service. Under the restricted stock agreements, the restricted shares will vest annually over a four-year period and will be payable in stock, valued at the fair market value on the grant date.

As of June 30, 2018, the following shares had been issued under the 2013 RSU Plan:

Year of Issuance:	Number of Shares		Fair Value at Date of Grant		Shares Vested		Non-Vested		Cancelled
2013		120,000	$	26,400		115,000		–		5,000
2014		122,100	$	30,946		101,850		–		20,250
2015		150,000	$	39,000		85,000		15,000		50,000
2016		–		–		–		–		–
2017		563,000	$	114,030		111,600		45,000		406,400
2018		80,000	$	11,192		–		80,000		–
		1,035,100	$	221,568		413,450		140,000		481,650

4. Commitments and Contingencies

Operating Leases

The Company leases their pharmacy, corporate offices and certain pharmacy equipment under non-cancelable operating lease agreements. Certain leases contain renewal options and provide that the Company pay taxes, insurance, maintenance and other operating expenses.

Minimum lease payments under all non-cancelable operating lease agreements for the six months ended June 30, 2018, are as follows:

2018	$	785,000
2019		803,000
2020		678,000
2021		671,000
2022		682,000
Thereafter		3,508,000
	$	7,127,000

Legal Proceedings

The Company is occasionally involved in other claims and proceedings, which are incidental to its business. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

5. Related Party Transactions

During the three and six months ended June 30, 2018, the Company paid fees to its directors of $12,000 and $28,000 for their roles as members of the Board of Directors and its related committees; fees paid to the Company’s Chairman totaled $30,000 and $60,000 for management and other services provided.

6. Subsequent Events

On August 1, 2018, Dougherty’s Pharmacy, Inc. (the “Company”) was obligated to make payment of the outstanding principal of $3,956,193 plus $18,252 in accrued and unpaid interest under a $4,000,000 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “Lender”). Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,251.80 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver.

On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender, or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

The forward-looking statements contained in this Form 10-Q and other documents that we file or furnish with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the Company’s website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications.

Statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the expected execution and effect of our business strategies. Words such as “expect,” “likely,” “outlook,” “forecast,” “preliminary,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “goal,” “guidance,” “continue,” “sustain,” “synergy,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to the following:

	·	We are in default under our revolving credit facility, which jeopardizes our ability to continue current operations in the event that the lender elects to foreclose against the Company’s material assets securing this indebtedness; We have limited funds and will require additional financing to maintain our current operations;
	·	We may not be able to effectively integrate and manage our current and anticipated growth strategies;
	·	We could be subject to unforeseen costs associated with our Pharmacy Acquisitions which could reduce our profitability;
	·	We may enter into additional leveraged transactions in connection with future Pharmacy Acquisitions;
	·	We may be negatively affected by restrictive terms and covenants in our existing credit facility;
	·	We are substantially dependent on a single supplier of pharmaceutical products;
	·	We must maintain sufficient sales to qualify for favorable pricing under our long term supply contract;
	·	We may be affected by the introduction of new brand name and generic prescription drugs, the conversion rate and mix of prescriptions filled, the reimbursement rate by third party payors of prescriptions and increases in the cost to procure those drugs;
	·	We are subject to considerable uncertainty as to how current Health Reform Laws will affect our business and operations;
	·	We could be negatively affected by future legislative or regulator policies designed to manage healthcare costs or alter healthcare financing practices; and
	·	We handle confidential healthcare information for our customers and are subject to the risk in securing such confidential information and protecting it from cyber-attacks.

These and other risks, assumptions and uncertainties include, but are not limited to, those factors described in the “Risk Factors” sections of our Registration Statement on Annual Form 10-K filed on March 29, 2018. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date the statement.

OVERVIEW

Key measures used by the Company’s management to evaluate business performance include revenue, gross profit, selling, general and administrative expense (“SG&A”) and EBITDA. EBITDA is calculated as net income before deducting interest, taxes, depreciation and amortization. EBITDA is a non-GAAP measure that the Company’s management considers to best present the results of ongoing operations and is useful when comparing the performance between different reporting periods. In those instances, we have identified when the Company is presenting adjusted EBITDA. Although EBITDA is not a measure of actual cash flow because it does not consider changes in assets and liabilities that may impact cash balances, the Company believes it is a useful metric to evaluate operating performance and has therefore included such measures in the discussion of operating results below.

The Company also tracks prescriptions sold to assess operational performance.

Overview of Our Business

Dougherty’s Pharmacy, Inc. (“Dougherty’s,” which is also referred to in this Quarterly Report on Form 10-Q as “we,” “us,” or “the Company”) is a value oriented company focused on successfully acquiring, managing and growing community based pharmacies in the Southwest Region. Our wholly owned subsidiary, Dougherty’s Holdings, Inc., owns and operates multiple Dougherty’s Pharmacies, which we operate as a single segment in our financial reporting. The flagship store, Dougherty’s Pharmacy, is a turn-key multi-service pharmacy located in a highly prestigious area of Dallas, Texas. Centrally located, we believe that Dougherty’s Pharmacy continues to provide a level of service not typically provided by national pharmacy chain stores. We fulfill virtually any prescription need, from the simplest to the most complex compounding prescriptions. Most national pharmacy chains do not provide complex pharmacy prescription services. We specialize in providing solutions for our retail customers’ pharmacy needs and also for our customers residing in assisted living facilities. Dougherty’s long history began in 1929 and continues today as one of Dallas’s oldest, largest and best-known full-service pharmacies, which also includes durable medical equipment, home healthcare products services, and health and wellness supplements. We have a customer service oriented philosophy and typically do not attempt to compete solely based on price, as is the case with most of the national pharmacy chains.

Additional community pharmacies are located in Dallas, El Paso, and Springtown, Texas and in McAlester, Oklahoma.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

The following discussion explains the material changes in our results of operations for the three months ended March 31, 2018 and 2017, and the significant developments affecting our financial condition since the Form 10-K filed March 29, 2018. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2017 and 2016 filed in that report, along with this report.

Comparison of the Three and Six months ended June 30, 2018, to the Three and Six months ended March 31, 2017 (000’s Omitted)

	Three Months ended June 30,						Six Months Ended June 30,
	2018			2017			2018				2017

Revenue	$	9,168		$	10,211		$	18,623		$	20,266
Cost of sales		6,894			7,448			13,781			14,716
Gross profit		2,274			2,763			4,842			5,550
Operating expenses
Selling, General and Administrative		2,432			2,627			4,941			5,203
Depreciation and amortization		240			254			482			520
Other income		51			–			88			–
Interest income		33			12			33			12
Interest expense		111			112			221			214
Loss of disposal of assets		–			75			–			75
Income tax provision		6			12			16			23
Net loss	$	(431	)	$	(305	)	$	(697	)	$	(473)
plus:
Interest expense	$	111		$	112		$	221		$	214
Depreciation and amortization		240			254			482			520
Loss on disposal of assets		–			75			–			75
Income tax provision		6			12			16			23
EBITDA (Adjusted)	$	(74	)	$	148		$	22		$	359

Prescription count		101,176			109,376			204,271			220,521

Revenues

Net revenues decreased approximately $1,043,000 or 10.2%, and $1,643,000, or 8.1% in the three and six months ended June 30, 2018. Retail pharmacy prescriptions sold decreased 8,200 or 7.5% and 16,250 or 7.4% for the three and six months ended June 30, 2018. Net revenues and prescriptions for the three months ended June 30, 2017 includes $53,000 and 649, respectively, and for the six months ended June 30, 2018 includes $177,000 and 2,313, respectively, from the Humble, Texas pharmacy, sold on May 6, 2017. Net revenues for the three and six months ended June 30, 2018 includes $23,000 and $34,000, respectively, of front-end sales at the Legacy store, opened February 6, 2018 and also $30,000 and $49,000, respectively, of net retail pharmacy revenues and 803 and 1,263, respectively, prescriptions filled for the Legacy store via concierge service from its pharmacy on Campbell Road. For the three and six months ended June 30, 2018, net revenues and retail pharmacy prescriptions declined $1,013,000 and 7,551, respectively, and $1,500,000 and 13,937, respectively, after adjusting for the Humble, Texas and Legacy stores, primarily attributable to the transition of prescriptions filled for certain long-term care facilities and under certain third party payor benefit plans that changed effective January, 2018, to other pharmacy providers. The initial focus of the Managing Director of Business Development appointed during the first quarter of 2018 is to recoup these prescriptions.

Gross profit

Gross profit dollars decreased $489,000, or 17.7%, and $708,000, or 12.8% in the three and six months ended June 30, 2018, as compared to prior year. Gross profit as a percent of revenues decreased 230 basis points for the three months ended June 30, 2018, to 24.8%, as compared to prior year. Gross profit as a percentage of net revenues decreased approximately 140 basis points in the six months ended June 30, 2018 to 26.0%, as compared to prior year as a result of reduced reimbursement from certain third party payor benefit plans that changed effective January, 2018 and continued increases in third party payor fees. Total third party fees for the three and six months June 30, 2018, ended increased $154,000 and $189,000 as compared to prior year. Net Direct and Indirect Remuneration fees during the three and six months ended June 30, 2018 were comparable to the same quarter prior year.

SG&A expenses

SG&A expenses decreased $195,000, or 7.4% and $262,000, or 5.0% for the three and six months ended June 30, 2018, as compared to prior year. SG&A expenses as a percentage of revenues for both the three and six months ended June 30, 2018, increased to 26.5% as compared to 25.7% prior year. The decrease in SG&A expenses during the three months ended June 30, 2018, is due to salary and payroll related cost savings from the resignations of the President of Pharmacy Operations and President and Chief Financial Officer during the fourth quarter of 2017 and first quarter of 2018, respectively, offset by the addition of the Managing Director of Business Development during the first quarter of 2018. The increase in operating expenses as a percentage of revenues is due to lower revenue as compared to prior year. Management plans to continue cost reduction initiatives during 2018 to decrease SG&A expenses as a percentage of revenues.

Earnings Before Interest, Taxes, Depreciation and Amortization

EBITDA decreased $222,000, or 150.0% and $337,000, or 93.9%, respectively, for the three and six months ended June 30, 2018, as compared to the same periods prior year. EBITDA as a percentage of revenues decreased 230 basis points for the three months ended June 30, 2018, to -0.8%, as compared to prior year. EBITDA as a percentage of net revenues decreased approximately 170 basis points in the six months ended June 30, 2018 to 0.1%, as compared to prior year. The decrease in EBITDA basis points for the three and six months ended June 30, 2018, compared to the same period during prior year, is a result of corresponding decreases in gross profit discussed above.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2018, we had working capital of approximately negative $2.6 million as compared to working capital of approximately negative $2.0 million at December 31, 2017. Negative working capital is due to the reclassification of the Revolver balance of $3.9 million and $3.8 million as of June 30, 2018 and December 31, 2017, respectively, to current liabilities to present the consolidated financial statements in conformity with GAAP (See Note 2). The reclassification does not affect the representation of the Company’s overall performance. The net increase in negative working capital of $0.6 million is discussed below. See Note 6 in Item 1of the Financial Statements included in Part 1 of the Financial Information above.

As of June 30, 2018, we had cash of approximately $54,000 as compared to $389,000, of which $303,000 was restricted, at December 31, 2017. The net decrease in cash for the three months ended June 30, 2018, of $335,000 was due to the use of cash provided by operating activities for capital expenditures discussed below.

As of June 30, 2018, the Company had total current assets of $5,306,000 and total current liabilities of $7,887,000 creating negative working capital of approximately $2,581,000 as compared to total current assets of $6,242,000 and total current liabilities of $8,196,000 creating negative working capital of approximately $1,954,000 at December 31, 2017. The overall increase in negative working capital of $627,000 is primarily due to decreases in cash, trade accounts receivable and inventory as a result of the decline in revenues discussed above.

The change in cash and cash equivalents is as follows:

	Six Months Ended June 30,
	2018				2017

Net cash provided by operating activities	$	244		$	472
Net provided by (used in) investing activities		(124	)		818
Net cash used in financing activities		(455	)		(900	)
Net increase (decrease) increase in cash	$	(335	)	$	390

Net cash provided by operating activities was approximately $244,000 in the six months ended June 30, 2018, compared to $472,000 in the three months ended June 30, 2017. The decrease of $228,000 was primarily related to the decline in revenues discussed in “Revenues” above resulting in an increase in net loss of $224,000, a decrease in cash used by inventory of $528,000 and an increase in cash used by accounts payable of $502,000, and net decreases in cash provided by other changes of $30,000.

Net cash (used in) provided by investing activities was approximately $124,000 for the three months ended June 30, 2018, compared to $818,000 in the six months ended June 30, 2017. Cash used to purchase property and equipment was $124,000 for the six months ended June 30, 2018, compared to $73,000 for the prior year due to capital expenditures to open the new retail pharmacy location at The Campus at Legacy West in Plano, Texas, to expand long-term care facilities and for upgrades to the Preston Royal, Dallas, Texas location. For the six months ended June 30, 2017, cash provided by the proceeds of the disposition of the Humble, Texas location was $274,000 and CPOC was $617,000.

Net cash used in financing activities was $455,000 in the six months ended June 30, 2018, compared to $900,000 for the same period in 2017. For the six months ended June 30, 2018, borrowings of $7,956,000 and payments of $7,926,000 were made on the revolving credit facility; payments of $485,000 were made on notes payable. For the six months ended June 30, 2017, borrowings of $9,426,000 and payments of $9,631,000 were made on the revolving credit facility; payments of $695,000 were made on notes payable. Certain proceeds from the disposition of CPOC were used to make certain payments on notes payable for the three months ended March 31, 2017.

Our principal indebtedness at June 30, 2018, consists of the following:

	·	A number of term notes in favor of Cardinal Health in the aggregate amount of $3,072,000, secured by certain retail pharmacy assets, and maturing between August 2019 and August 2020;
	·	A revolving credit facility under which the Company has currently borrowed $3,861,000.

The material terms under these agreements include, without limitation, notice requirements for certain material events, the provision of periodic financial statements, the maintenance of certain financial ratios, maintaining certain minimum insurance requirements, as well as restrictions on our ability to incur additional indebtedness, incur future capital expenditures, as well as restrictions on our ability purchase, create or acquire any interest in any other pharmacy store or distributing company, or loan, invest in or advance money or assets to any other person, enterprise or entity for the acquisition of a pharmacy store or distributing company without the prior written consent of the First National Bank of Omaha.

In addition, the Company was a co-guarantor on a promissory note issued by a bank in favor of an individual who was previously, through August of 2008, a related party of the Company. On April 3, 2018, total principal amount due and owing under the promissory note (the “Guarantee Payment”), was satisfied in full by the primary obligor. The restricted cash balance of $304,000, for which the Company was required to provide as escrow, was released as unrestricted and used for operations. In conjunction with the satisfaction of the of the obligation and release of restricted funds, the primary obligor paid the Company $33,000 interest for the 11 months ended March 31, 2018 during April of 2018 and $12,000 for the three months ended March 31, 2017 during May of 2017.

On August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,193 plus $18,252 in accrued and unpaid interest under the Revolver with the Lender. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,251.80 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver.

On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender, or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company.

Tax Loss Carryforwards

At December 31, 2017, we had approximately $48 million of federal net operating loss carryforwards available to offset future taxable income, which, if not utilized, will fully expire from 2020 to 2037. We believe that the issuance of shares of our common stock pursuant to our initial public offering on November 15, 1999 caused an “ownership change” for purposes of Section 382 of the Internal Revenue Code of 1986, as amended. Consequently, we believe that the portion of our federal NOL carryforwards attributable to the period prior to November 16, 1999 is subject to an annual limitation pursuant to Section 382. Our total deferred tax assets have been fully reserved as a result of the uncertainty of future taxable income, except for $2 million that is estimated to offset future taxable income from pharmacy operations and or the sale of pharmacy businesses. The estimated deferred tax asset as of March 31, 2018 is consistent with December 31, 2018; accordingly, no tax benefit has been recognized in the periods presented.

Off Balance Sheet Arrangements

We do not have any unconsolidated special purpose entities and, except as described herein, we do not have significant exposure to any off-balance sheet arrangements. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgment. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our significant accounting policies, please refer to the Notes to Consolidated Financial Statements in Item 1.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our interim chief executive officer and interim chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a–15(e) under the Exchange Act) as of June 30, 2018. Based upon that evaluation, our interim chief executive officer and interim chief financial officer concluded that as of June 30, 2018, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 6. Exhibits

Exhibit Number		Description

31.1		Certification of the President - Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

32		Certification of the President - Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)

101.INS		XBRL Instances Document (1)
101.SCH		XBRL Taxonomy Extension Schema Document (1)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)	Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Company has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized on August 14, 2018.

	DOUGHERTY’S PHARMACY, INC.


	By:	/s/ James C. Leslie
		James C. Leslie
		Interim President and Chief Financial Officer (Duly Authorized Principal Executive Officer and Principal Financial Officer)

EXHIBIT INDEX

Exhibit Number		Description

31.1		Certification of the President - Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

32		Certification of the President - Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)

101.INS		XBRL Instances Document (1)
101.SCH		XBRL Taxonomy Extension Schema Document (1)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)	Filed herewith.

Dougherty's Pharmacy, Inc. 10-Q